Cyclooxygenase-2 directly induces MCF-7 breast tumor cells to develop into exponentially growing, highly angiogenic and regionally invasive human ductal carcinoma xenografts

Fredika M. Robertson, Susan R. Mallery, Valerie K. Bergdall-Costell, Mark Cheng, Ping Pei, Jenifer Prosperi, Mauro Ferrari

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Based on our studies demonstrating first time evidence that the cyclooxygenase-2 (Cox-2) enzyme is abundant within invasive human breast tumors, we developed a clonally derived human breast tumor cell clone designated as MCF-7/Cox-2 Clone 10 by transfection of human Cox-2 cDNA into slow growing, Cox-2 null, non-metastatic MCF-7 human breast tumor cells. The present studies evaluated the biological characteristics of the MCF-7/Cox-2 Clone 10 human breast tumors compared to the characteristics of MCF-7/empty vector control tumors when grown in vivo following infection of 5×106 tumor cells into mammary fat pads of ovariectomized female Crl:Nu-Foxn1nu mice implanted with slow release 17-β estradiol pellets. At 60 days after tumor cell injection, MCF-7/Cox-2 Clone 10 human breast tumors were 4-fold greater (pnu mice at 42-60 days which recapitulate human breast ductal carcinomas. This unique model may be invaluable as a means to evaluate preclinical safety and efficacy of novel adjuvant therapies for women with metastastic breast cancer including prostanoid receptor antagonists, newly developed anti-angiogenic therapies, as well as other novel approaches for targeting and destruction of human breast tumors and their vasculature.

Original languageEnglish (US)
Pages (from-to)719-727
Number of pages9
JournalAnticancer Research
Volume27
Issue number2
StatePublished - Mar 2007
Externally publishedYes

Fingerprint

Ductal Carcinoma
Cyclooxygenase 2
Heterografts
Breast Neoplasms
Clone Cells
Carcinoma, Ductal, Breast
Neoplasms
MCF-7 Cells
Prostaglandins
Transfection
Adipose Tissue
Estradiol
Breast
Complementary DNA
Safety
Injections
Enzymes
Therapeutics
Infection

Keywords

  • Angiogenesis
  • Cyclooxygenase-2
  • Ductal carcinoma
  • Human breast cancer model
  • Invasion
  • MCF-7/Cox-2 Clone 10
  • Xenografts

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cyclooxygenase-2 directly induces MCF-7 breast tumor cells to develop into exponentially growing, highly angiogenic and regionally invasive human ductal carcinoma xenografts. / Robertson, Fredika M.; Mallery, Susan R.; Bergdall-Costell, Valerie K.; Cheng, Mark; Pei, Ping; Prosperi, Jenifer; Ferrari, Mauro.

In: Anticancer Research, Vol. 27, No. 2, 03.2007, p. 719-727.

Research output: Contribution to journalArticle

Robertson, Fredika M. ; Mallery, Susan R. ; Bergdall-Costell, Valerie K. ; Cheng, Mark ; Pei, Ping ; Prosperi, Jenifer ; Ferrari, Mauro. / Cyclooxygenase-2 directly induces MCF-7 breast tumor cells to develop into exponentially growing, highly angiogenic and regionally invasive human ductal carcinoma xenografts. In: Anticancer Research. 2007 ; Vol. 27, No. 2. pp. 719-727.
@article{e9d4bdf4d05343cfa4f7043edfc5a755,
title = "Cyclooxygenase-2 directly induces MCF-7 breast tumor cells to develop into exponentially growing, highly angiogenic and regionally invasive human ductal carcinoma xenografts",
abstract = "Based on our studies demonstrating first time evidence that the cyclooxygenase-2 (Cox-2) enzyme is abundant within invasive human breast tumors, we developed a clonally derived human breast tumor cell clone designated as MCF-7/Cox-2 Clone 10 by transfection of human Cox-2 cDNA into slow growing, Cox-2 null, non-metastatic MCF-7 human breast tumor cells. The present studies evaluated the biological characteristics of the MCF-7/Cox-2 Clone 10 human breast tumors compared to the characteristics of MCF-7/empty vector control tumors when grown in vivo following infection of 5×106 tumor cells into mammary fat pads of ovariectomized female Crl:Nu-Foxn1nu mice implanted with slow release 17-β estradiol pellets. At 60 days after tumor cell injection, MCF-7/Cox-2 Clone 10 human breast tumors were 4-fold greater (pnu mice at 42-60 days which recapitulate human breast ductal carcinomas. This unique model may be invaluable as a means to evaluate preclinical safety and efficacy of novel adjuvant therapies for women with metastastic breast cancer including prostanoid receptor antagonists, newly developed anti-angiogenic therapies, as well as other novel approaches for targeting and destruction of human breast tumors and their vasculature.",
keywords = "Angiogenesis, Cyclooxygenase-2, Ductal carcinoma, Human breast cancer model, Invasion, MCF-7/Cox-2 Clone 10, Xenografts",
author = "Robertson, {Fredika M.} and Mallery, {Susan R.} and Bergdall-Costell, {Valerie K.} and Mark Cheng and Ping Pei and Jenifer Prosperi and Mauro Ferrari",
year = "2007",
month = "3",
language = "English (US)",
volume = "27",
pages = "719--727",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "2",

}

TY - JOUR

T1 - Cyclooxygenase-2 directly induces MCF-7 breast tumor cells to develop into exponentially growing, highly angiogenic and regionally invasive human ductal carcinoma xenografts

AU - Robertson, Fredika M.

AU - Mallery, Susan R.

AU - Bergdall-Costell, Valerie K.

AU - Cheng, Mark

AU - Pei, Ping

AU - Prosperi, Jenifer

AU - Ferrari, Mauro

PY - 2007/3

Y1 - 2007/3

N2 - Based on our studies demonstrating first time evidence that the cyclooxygenase-2 (Cox-2) enzyme is abundant within invasive human breast tumors, we developed a clonally derived human breast tumor cell clone designated as MCF-7/Cox-2 Clone 10 by transfection of human Cox-2 cDNA into slow growing, Cox-2 null, non-metastatic MCF-7 human breast tumor cells. The present studies evaluated the biological characteristics of the MCF-7/Cox-2 Clone 10 human breast tumors compared to the characteristics of MCF-7/empty vector control tumors when grown in vivo following infection of 5×106 tumor cells into mammary fat pads of ovariectomized female Crl:Nu-Foxn1nu mice implanted with slow release 17-β estradiol pellets. At 60 days after tumor cell injection, MCF-7/Cox-2 Clone 10 human breast tumors were 4-fold greater (pnu mice at 42-60 days which recapitulate human breast ductal carcinomas. This unique model may be invaluable as a means to evaluate preclinical safety and efficacy of novel adjuvant therapies for women with metastastic breast cancer including prostanoid receptor antagonists, newly developed anti-angiogenic therapies, as well as other novel approaches for targeting and destruction of human breast tumors and their vasculature.

AB - Based on our studies demonstrating first time evidence that the cyclooxygenase-2 (Cox-2) enzyme is abundant within invasive human breast tumors, we developed a clonally derived human breast tumor cell clone designated as MCF-7/Cox-2 Clone 10 by transfection of human Cox-2 cDNA into slow growing, Cox-2 null, non-metastatic MCF-7 human breast tumor cells. The present studies evaluated the biological characteristics of the MCF-7/Cox-2 Clone 10 human breast tumors compared to the characteristics of MCF-7/empty vector control tumors when grown in vivo following infection of 5×106 tumor cells into mammary fat pads of ovariectomized female Crl:Nu-Foxn1nu mice implanted with slow release 17-β estradiol pellets. At 60 days after tumor cell injection, MCF-7/Cox-2 Clone 10 human breast tumors were 4-fold greater (pnu mice at 42-60 days which recapitulate human breast ductal carcinomas. This unique model may be invaluable as a means to evaluate preclinical safety and efficacy of novel adjuvant therapies for women with metastastic breast cancer including prostanoid receptor antagonists, newly developed anti-angiogenic therapies, as well as other novel approaches for targeting and destruction of human breast tumors and their vasculature.

KW - Angiogenesis

KW - Cyclooxygenase-2

KW - Ductal carcinoma

KW - Human breast cancer model

KW - Invasion

KW - MCF-7/Cox-2 Clone 10

KW - Xenografts

UR - http://www.scopus.com/inward/record.url?scp=34247128314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247128314&partnerID=8YFLogxK

M3 - Article

C2 - 17465194

AN - SCOPUS:34247128314

VL - 27

SP - 719

EP - 727

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 2

ER -